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1. Introduction 
In 2007 the Centers for Disease Control and Prevention placed Neisseria gonorrhoeae on the 
infamous “Super Bugs” list to highlight the high prevalence of strains resistant to relatively 
inexpensive antibiotics, such as penicillin, tetracycline and fluoroquinolones, previously 
used in therapy to treat gonorrhea (Shafer et al., 2010). This event was significant because 
the gonococcus, a strict human pathogen, causes > 95 million infections worldwide each 
year and since the mid-1940s mankind has relied on effective antibiotic therapy to treat 
infections and stop local spread of disease. Today, such therapy is threatened by antibiotic 
resistance. Specifically, the third generation cephalosporins, especially ceftriaxone, may be 
losing their effectiveness since some (albeit still rare) isolates in the Far East, most recently 
Japan, and Europe have displayed clinical resistance to currently used levels of ceftriaxone, 
and treatment failures have been reported (Ohnishi et al., 2011; Unemo et al., 2010). Concern 
has been raised that the spectrum of resistance expressed by some gonococcal strains may 
make standard antibiotic treatment for gonorrhea ineffective in the not too distant future 
(Dionne-Odom et al., 2011). Without new, effective antibiotics or novel combination 
therapies of existing antibiotics, the reproductive health of the world’s sexually active 
population may be placed at risk due to such antibiotic resistant gonococci. 
An important question regarding antibiotic resistance is whether a particular resistance 
mechanism has a fitness cost for the bacterium (Andersson & Levin, 1999; Andersson & 
Hughes, 2010), especially in the community where it competes with its antibiotic sensitive 
brethren. A fitness cost is typically experimentally measured as a deleterious change in 
bacterial growth rate in laboratory media or survival in experimental infection in the 
absence of antibiotic pressure. Fitness costs (or benefits) are best viewed during co-
cultivation of isogenic strains that differ only in the resistance mechanism under study. For 
certain antibiotic resistance mechanisms, a significant fitness cost can be incurred. This 
general observation led to the idea that removal of the selective pressure imposed by the 
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antibiotic in question would favor sensitive strains to predominate in the community and 
allow for the return of the antibiotic in question to treat the infection in question. By and 
large, this has proven not be the case (Andersson and Hughes, 2010). There are many 
reasons for this, including the unintentional selective pressure exerted by the widespread 
availability and use of antibiotics to treat bacterial infections in general, over-the-counter 
antimicrobials that confer selective pressure and provide cross-resistance (or decreased 
susceptibility) to the antibiotic in question, and host-derived antimicrobials that select for 
the particular resistance determinant. In addition to antimicrobial pressures, it has been 
repeatedly documented that compensatory, second site mutations can develop that reverse 
fitness costs while maintaining resistance (Schrag et al., 1997; Marcusson et al., 2009; 
Andersson and Hughes, 2010). 
More recently, a new view has been taken regarding antibiotic resistance and fitness: some 
resistance systems actually provide the resistant strain with a fitness advantage over wild-
type strains or can reverse a fitness burden imposed by a separate mutation that also 
participates in resistance to a particular antibiotic. Evidence for enhanced fitness of bacterial 
pathogens, in laboratory media or in experimental infection models, due to mutations or 
gene acquisition events that increase resistance to antibiotics has been provided for 
Campylobacter jejuni (Luo et al., 2005) and Neisseria gonorrhoeae (Warner et al., 2007, 2008). 
The idea that an antibiotic resistance mechanism could have negligible and even beneficial 
effects on fitness could help to explain, in part, why resistant strains persist in the 
community long after the antibiotic has been removed from the treatment regimen. For 
instance, gonococci expressing resistance to penicillin, tetracycline and/or fluoroquinolones 
have persisted in the community despite the removal of these antibiotics from the 
recommended gonorrhea treatment regimen for several years. Against this background, we 
herein review data and provide models as to how two mechanisms of antibiotic resistance 
expressed by N. gonorrhoeae can enhance fitness in vivo. The in vivo system employed in 
these studies is a female mouse model of lower genital tract infection that recapitulates 
many features of infection in human females, most notably the development of 
inflammation that occurs during cervicitis (Jerse, 1999; Packiam et al., 2010; Song et al., 
2008). The two resistance mechanisms discussed below are multi-drug efflux by the MtrC-
MtrD-MtrE pump (Hagman et al., 1995; Jerse et al., 2003) and quinolone resistance that 
develops due to point mutations in gyrA and parC. We discuss concepts regarding the 
evolution of antibiotic resistance expressed by gonococci in the context of how these 
resistance mechanisms may have endowed this strict human pathogen with a fitness 
advantage during infection. 
2. Antimicrobial efflux and gonococcal fitness 
The MtrC-MtrD-MtrE efflux pump of N. gonorrhoeae is a resistance-nodulation-division 
(RND) efflux pump family member that recognizes a diverse array of hydrophobic 
antimicrobial agents and exports these toxic compounds out of the gonococcal cell (Hagman 
et al., 1995). The mtrCDE operon is composed of three structural genes that encode the core 
proteins of the efflux pump: mtrC, which encodes a periplasmic membrane fusion protein; 
mtrD, encoding an energy-dependent inner membrane transporter; and mtrE, which 
encodes a TolC-like outer membrane channel protein (Delahay et al., 1997; Hagman et al., 
1995; Hagman et al., 1997). In addition to these core efflux proteins, an accessory protein 
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termed MtrF is required for high-level resistance to substrates of the pump and its gene 
(mtrF) is also located within the mtr locus (Figure 1) (Veal & Shafer, 2003). 
 
Fig. 1. Organization of the mtr locus of N. gonorrhoeae. Bent arrows mark the mtrR, mtrF, 
and mtrCDE promoters. mtrR and mtrCDE are divergently transcribed on opposite strands. 
Circles represent the transcriptional regulatory proteins MtrR and MtrA. The box represents 
the location of the expanded sequence. The mtrR and mtrCDE promoter elements are 
indicated in the expanded sequence; the dashed box marks the inverted repeat element of 
the mtrR promoter. 
Transcription of the mtrCDE operon is negatively regulated by the TetR family 
transcriptional regulator, MtrR, which represses mtrCDE expression by the binding of two 
homodimers to pseudo-direct repeats within the mtrCDE promoter (Hoffman et al., 2005; 
Lucas et al., 1997). The mtrR gene is located 250 base pairs upstream of and is transcribed 
divergently from mtrCDE (Pan & Spratt, 1994). Additionally, transcription of mtrCDE may 
be induced in the presence of sub-lethal concentrations of nonionic, membrane-acting 
detergents through the action of an AraC/XylS family transcriptional activator, MtrA 
(Rouquette et al., 1999). Expression of mtrF is negatively regulated by both MtrR and the 
AraC family regulator MpeR (Folster and Shafer, 2005), as well as the availability of free iron 
(Mercante et al., 2012). 
The MtrC-MtrD-MtrE efflux pump mediates resistance to structurally diverse hydrophobic 
antimicrobial agents, including ß-lactam antibiotics such as penicillin, macrolide antibiotics 
including erythromycin and azithromycin, dyes such as crystal violet, and detergents such 
as Triton X-100 and nonoxynol-9 (Hagman et al., 1995; Rouquette et al., 1999). Additionally, 
MtrC-MtrD-MtrE confers resistance to host antimicrobial compounds, including fatty acids, 
bile salts, progesterone, and the antimicrobial peptide LL-37 (Jerse et al., 2003; Morse et al., 
1982; Shafer et al., 1995; Shafer et al., 1998). MtrC-MtrD-MtrE efflux pump-deficient mutants 
are highly attenuated in a female BALB/c mouse model of lower genital tract infection, even 
in the absence of pump substrate antibiotic treatment (Jerse et al., 2003). This attenuation is 
likely due to an increased susceptibility to host antimicrobial compounds, highlighting the 
importance of the mtr system in establishing gonococcal infection. 
The production of efflux pumps is an energy-expensive process, and it might be 
hypothesized that high levels of MtrC-MtrD-MtrE production could stress the gonococcus, 
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resulting in slower or defective growth, thereby conferring a fitness cost on strains with 
increased mtrCDE expression. In this respect, Eisenstein and Sparling noted that a mutant 
strain displaying the Mtr phenotype, now known to be due to a single base pair deletion in 
the inverted repeat in the mtrR promoter (Figure 1) that results in high-level antibiotic 
resistance through increased transcription of mtrCDE (Hagman & Shafer, 1995), had a 
slower growth rate in vitro (Eisenstein & Sparling, 1978). However, this same mutation 
confers a fitness advantage during competitive infection against wild-type strain FA19 in the 
female mouse model of infection in the absence of antibiotics (Warner et al., 2008) and is 
frequently found in clinical isolates (Shafer et al., 1995; Zarantonelli et al., 1999), particularly 
from men who have sex with men (Shafer et al., 1995; Xia et al., 2000). Additional mutations 
in the mtrR coding region and the mtrR promoter have been identified in clinical isolates 
that increase resistance to MtrC-MtrD-MtrE pump substrates as well as confer a survival 
advantage in the female mouse infection model (Table 1) (summarized in Warner et al., 
2008). Mutations in the mtrR coding region, particularly those resulting in radical amino 
acid changes in the MtrR helix-turn-helix DNA binding domain, lead to low or intermediate 
levels of antimicrobial resistance that corresponds to a low to intermediate survival 
advantage during competitive infection in female mice (Warner et al., 2008). The single 
nucleotide deletion in the inverted repeat of the mtrR promoter and a recently identified 
mutation 120 base pairs upstream of the mtrC start codon (mtr120) confer high-level 
resistance to pump substrates as well as a greater fitness advantage in vivo (Warner et al., 
2008). These changes in fitness require an active efflux pump, as the effects were reversed in 
the regulatory mutant strains when the efflux pump system was genetically inactivated. 
Thus, it appears that the level of antibiotic resistance due to increased mtrCDE expression 
corresponds positively to the strength of the fitness advantage observed in vivo. 
 
Genotype CI at day 3 
Single bp deletion in mtrR promoter 1000 
mtr120 point mutation 1000 
A39T change in DNA binding domain of MtrR 100 
mtrA::KmR 0.005 
mtrA::KmR mtrR1-53 100 
mtrA::KmR mtrRE202G 10 
mpeR::KmR 1 
Table 1. Fitness of mtr regulatory mutants in mice compared to wild-type. CI: competitive 
index. Ratio of mutant to wild-type CFU (vaginal isolates) divided by mutant to wild-type 
CFU (inoculum). 
Induction of mtrCDE expression by the activator MtrA is also important for gonococcal 
survival in vivo. Strains carrying a disrupted mtrA gene display a significant fitness 
disadvantage during competitive infection with wild-type strain FA19 in the female mouse 
model of infection (Warner et al., 2007). MtrA induction of mtrCDE expression occurs in the 
presence of nonionic detergents such as Triton X-100 (Rouquette et al., 1999). The presence 
of host antimicrobial factors that are pump substrates, such as fatty acids or CRAMP-38, the 
mouse homologue of the human cathelicidin LL-37, may have a similar effect. The decreased 
fitness of the mtrA mutants in vivo would therefore be attributed to failure of the gonococcus 
to respond to host defense factors due to inability to upregulate expression of the pump. 
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Interestingly, in a study by Warner et al., 2007, some mtrA-deficient strains developed 
mutations in the mtrR gene (mtrR1-53 and mtrRE202G) after inoculation into mice in the absence 
of antibiotics; these strains were recovered in high numbers and displayed increased 
antibiotic resistance as well as a fitness advantage during subsequent competitive infection 
against wild-type FA19 (Table 1). The development of compensatory mutations to overcome 
the cost of mtrA disruption highlights the importance of the MtrC-MtrD-MtrE efflux pump 
to gonococcal fitness in vivo. 
The importance of the MtrC-MtrD-MtrE efflux pump in vivo, even in the absence of 
antibiotic treatment, suggests that this pump originally evolved as a mechanism to aid the 
gonococcus in escaping host defense mechanisms, rather than in response to the 
introduction of antibiotics to treat gonococcal infection. Increasing antibiotic use and the 
availability of the over-the-counter spermicide nonoxynol-9 may then have selected for 
pump mutants, such as those containing mtrR mutations frequently isolated from patients 
with gonococcal infection. These strains are not only able to resist antibiotic treatment, but 
also better able to resist host antimicrobial compounds, giving them a survival advantage in 
vivo and in the community (Xia et al., 2000). Thus, increased production of the MtrC-MtrD-
MtrE efflux pump represents a mechanism of antibiotic resistance that imparts a fitness 
advantage upon the gonococcus, rather than a fitness cost. It is important to note that 
homologues of both the pump and its regulatory proteins exist in other Gram-negative 
bacteria. For example, the AcrA-AcrB-TolC efflux system of Salmonella enterica enhances the 
capacity of this pathogen to cause experimental infection in chickens (Webber et al., 2009). 
Lessons learned with the gonococcus regarding drug efflux and fitness may therefore have 
broader implications for how bacterial pathogens escape both classical antibiotics and host 
defense compounds. 
3. Quinolone resistance and gonococcal fitness 
The limited use of quinolones in the treatment of bacterial infections began after the 1962 
discovery of nalidixic acid as a product of chloroquine synthesis. Subsequent development 
of fluoroquinolone derivatives amassed broad-spectrum appeal due to their effective 
targeting of many Gram-positive and Gram-negative pathogens (Emmerson, 2003). 
Continued development of this class of antibiotics was fueled by the concurrent progression 
of bacterial resistance to penicillin and tetracycline, including N. gonorrhoeae (Covino et al., 
1990). By 1993, fluoroquinolones were recommended by the CDC as the first-line treatment 
option for uncomplicated gonococcal infections; however, within 10 years, over 80% of 
gonococcal isolates in the western Pacific region were ciprofloxacin resistant (CipR) (Tapsall, 
2005; Trees et al., 2001). The eventual spread of quinolone resistant N. gonorrhoeae (QRNG) in 
the United States led to the removal of fluoroquinolones from the list of recommended first-
line antibiotics for treatment of gonorrhea and related conditions by the CDC in 2007 (CDC, 
2007).  
Quinolones induce bacterial cell death by inhibiting the activity of the bacterial type IIA 
DNA topoisomerases DNA gyrase and topoisomerase IV (Emmerson, 2003; Hooper 1999). 
These enzymes are responsible for managing the topological state of genomic DNA and are 
necessary for resolving regions of topological stress that occur during critical cell processes 
such as DNA replication and the regulation of gene expression. DNA gyrase and 
topoisomerase IV are heterotetramers that bind to DNA and generate a double-stranded 
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break in one region of the bound DNA duplex, which results results in a complex referred to 
as the G-segment. A second region of distant DNA duplex, referred to as the T-segment, 
passes through the G-segment and the cleaved substrate held in the G-segment is 
subsequently religated to complete a single round of topological adjustment (Bates et al., 
2011; Chen and Lo 2003; Morais Cabral et al., 1997). Quinolones specifically target the G-
segment of the enzyme-DNA complex. Presently, there is no universally accepted 
mechanism of how quinolones kill bacteria; however, mounting evidence suggests that two 
quinolone molecules stabilize the cleaved DNA duplex, resulting in the accumulation of 
lethal lesions within the genome of the cell (Laponogov et al., 2009).  
Quinolone resistance in N. gonorrhoeae is due to point mutations in the quinolone resistance 
determining region (QRDR) of the A subunits of DNA gyrase (gyrA) and topoisomerase IV 
(parC) (Tanaka et al., 2000; Trees et al., 2001). Belland and colleagues were the first to 
delineate the genetic basis of quinolone resistance in N. gonorrhoeae in 1994. By analyzing 
ciprofloxacin resistant (CipR) mutants selected in vitro, these investigators showed CipR in N. 
gonorrhoeae is a two step process in which intermediate level ciprofloxacin resistance (CipI) 
occurs via point mutations in gyrA that encode amino acid substitutions at positions Ser91 
and Asp95. CipI gyrA mutants then become CipR when point mutations occur in parC 
(Belland et al., 1994). This sequence of events is consistent with data from numerous 
molecular epidemiologic studies (Kam et al., 2003; Morris et al., 2009; Starnino et al., 2010; 
Tanaka, 1992; Trees et al., 2001; Vereshchagin et al., 2004). Analyses of clinical isolates have 
also provided insights into the nature of mutations directly associated with fluoroquinolone 
resistance in N. gonorrhoeae. Commonly isolated substitutions in the Ser91 position of the 
GyrA subunit include amino acids with bulky side chains (phenylalanine and tyrosine) and 
the hydrophobic leucine, while arginine is the most common substitution at position Asp95 
(Kam et al., 2003; Morris et al., 2009; Ruiz et al., 2001; Starnino et al., 2010; Tanaka et al., 
2000; Trees et al., 2001; Vereshchagin et al., 2004; Vernel-Paulillac et al., 2009). Double point 
mutations in gyrA that result in these amino acid substitutions are sufficient and also largely 
responsible for sterically hindering the intercalation of quinolone molecules (Xiong et al., 
2011). The location specificity of parC mutations that lead to high level CipR appears to be 
less stringent than mutations in gyrA, with alterations at position 91 (the most common), 86, 
87, or 88 identified among CipR isolates (Dewi et al., 2004; Morris et al., 2009; Tanaka et al., 
2000; Trees et al., 2001) (Figure 2). 
The impact of quinolone resistance mutations on microbial fitness has been studied in 
several bacterial species. Topoisomerase mutations often are associated with an in vitro 
fitness cost, although not all gyrA mutations or combinations of gyrA mutations or gyrA, 
parC mutations result in decreased growth in vitro (Bagel et al., 1999; Marcusson et al., 2009, 
Pope et al., 2008; Luo et al., 2005). Interestingly, in 2005 Zhang and colleagues showed gyrA 
mutations confer a fitness benefit to C. jejuni in vivo using a chicken intestinal colonization 
model (Luo et al., 2005). Based on this report and the wide prevalence of QRNG strains, we 
hypothesized that fluoroquinolone resistance mutations in N. gonorrhoeae may be 
accompanied by a transmission or survival advantage. To address the possibility that 
QRNG may be more fit in vivo, we constructed CipI and CipR mutants in N. gonorrhoeae 
strain FA19 that carry the commonly isolated gyrA (Ser91Phe and Asp95Asn) or gyrA 
(Ser91Phe and Asp95Asn) and parC (Asp86Asn) mutations, respectively, and measured their 
fitness relative to the CipS parent strain in the murine genital tract infection model. No in vitro 
www.intechopen.com
Clinically Relevant Antibiotic Resistance Mechanisms 
Can Enhance the In Vivo Fitness of Neisseria gonorrhoeae 
 
377 
 
Fig. 2. Evolution of quinolone resistance in N. gonorrhoeae. Quinolone resistance in N. 
gonorrhoeae is a two-step process, beginning with point mutations in the QRDR of gyrA, which 
increase resistance to intermediate levels. Positions 91 and 95 are most often altered, with 
Ser91Phe and Asp95Asn the most common substitutions. Other substitutions have also been 
reported. High level resistance occurs upon mutation of the QRDR of parC mutation. parC 
mutations carried by CipR gonococci most often cause amino acid substations at position 91, 
86, 87 or 88 (Kam et al., 2003; Ghanem et al., 2005; Morris et al., 2009; Ruiz 2001; Starnino et al., 
2010; Tanaka et al., 2000; Trees et al., 2001; Vereshchagin et al., 2004; Vernel-Paulillac 2009). 
fitness cost was associated with acquisition of the gyrA91/95 mutations based on comparing 
the growth rates of the gyrA91/95 mutant and the CipS wild-type strain, although a slight 
reduction (3-fold) in the recovery of the mutant was observed when co-cultured with the 
CipS wild-type strain (Table 2). Interestingly, however, the CipI gyrA91/95 mutant exhibited a 
clear fitness advantage in vivo as evidenced by high competitive indices (CIs) over time and 
the isolation of only CipI bacteria from some mice on days 5 and 7 post-inoculation. In 
contrast, the CipR gyrA91/95, parC86 mutant grew significantly more slowly in vitro and 
exhibited reduced fitness in vivo relative to the wild-type CipS strain (Table 2) (Kunz et al., In 
Press). 
 
Genotype CI at day 3  
gyrA91/95 5-fold increase; 30-fold increase on day 5 compared to CipS 
wild-type strain 
gyrA91/95, parC86 2-fold decrease compared to CipS wild-type strain 
gyrA91/95, mtrR-79 40-fold increase compared to CipS mtr-56mutant parent strain 
gyrA91/95, parC86, mtrR-79 50-fold decrease compared to CipS mtr-56 mutant parent strain 
Table 2. Fitness of FQ-R mutations in mice compared to wild-type or mtr mutant Gc. CI: 
competitive index. Ratio of mutant to wild-type CFU (vaginal isolates) divided by mutant to 
wild-type CFU (inoculum). 
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As discussed, it is well established that mtr locus mutations increase gonococcal fitness in 
the mouse model, and we therefore wondered whether the fitness benefit conferred by 
gyrA91/95 mutations would enhance the fitness advantage afforded by increased efflux of 
host substrates through the MtrC-MtrD-MtrE active efflux pump. Our alternative 
hypothesis was that increasing numbers of resistance mutations would impair growth to 
such an extent as to abrogate the fitness benefits associated with either resistance mutation. 
To test this hypothesis, we constructed gyrA91/95 and gyrA91/95, parC86 mutants in an mtr 
mutant of strain FA19 that carries a commonly isolated mtrR promoter mutation (the single 
base pair deletion in the mtrR promoter termed hereafter as mtrR-79). The gyrA91/95, mtrR-79 
mutant (CipI) showed no fitness difference compared to the mtrR-79 mutant parent strain in 
vitro, but significantly out-competed the mtrR-79 mutant during experimental murine 
infection. In contrast, the highly CipR gyrA91/95, parC86, mtrR-79 mutant was severely 
attenuated both in vitro and in vivo relative to the mtrR-56 mutant, with only mtrR-56 mutant 
gonococci recovered from a majority of mice 5 days after inoculation (Table 2) (Kunz et al., 
In Press). 
From these studies we conclude that the gyrA91/95 mutation confers a fitness benefit to N. 
gonorrhoeae that is independent of the MtrC-MtrD-MtrE efflux pump system, but that an 
additional parC86 mutation results in a net fitness cost. These data are intriguing and may 
help to explain the frequent isolation of CipR gonococci that also carry mtrR promoter or 
mtrR structural gene mutations, which has been interpreted by others as evidence that active 
efflux through the MtrC-MtrD-MtrE pump is another mechanism of fluoroquinolone 
resistance in N. gonorrhoeae (Dewi et al., 2004; Vereshchagin et al., 2004). The fact that we 
found no difference in the Cip MICs of the gyrA91/95 versus gyrA91/95, MtrR-79 mutants or of 
gyrA91/95, parC86 versus gyrA91/95, parC86, mtrR-79 mutants (Kunz et al., submitted), is strong 
genetic evidence that mtr mutations do not contribute to CipR in N. gonorrhoeae. Instead, the 
prevalence of CipR mtr strains may reflect increased microbial fitness conferred by these 
mutations.  
It is important to remember that while mutations in both gyrA and parC led to reduced 
fitness in the mouse model, compensatory mutations may occur in nature that restore fitness 
while maintaining high level CipR. There is much evidence that fitness compensation can 
occur in bacteria without loss of antibiotic resistance (Balsalobre et al., 2011; Bjorkholm et al., 
2001; Bjorkman et al., 1998; Giraud et al., 1999; Komp Lindgren et al., 2005; Marcussen et al., 
2009; Nagaev et al., 2001). In support of this possibility for QRNG, we have observed that 
while CipR gonococci were outcompeted by CipS (wild-type) or CipI bacteria in a majority of 
mice tested, only CipR gonococci were recovered from some mice (10-17%) as infection 
progressed in each of several experiments (Figure 3). To further investigate this observation, 
we analyzed CipR bacteria isolated on day 5 in pure culture from a mouse inoculated with a 
mixture of CipI (gyrA91/95, mtrR-79) and CipR (gyrA91/95, parC86, mtrR-79) mutants. 
Interestingly, these CipR bacteria grew better than the Cip I and CipR strains used to 
inoculate the mouse and the CipS mtr parent of the CipI and CipR strains. Unlike either of 
these strains, the in vivo-selected CipR mutant had a wild-type mtr locus and a gyrA allele 
that was predicted to encode a leucine instead of phenylalanine residue at position 91 
(Phe91Leu) (Kunz et al., In Press). We conclude that one or more compensatory mutations 
occurred during infection that allowed highly CipR gonococci to out-compete CipI bacteria 
in vivo. 
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Fig. 3. The fitness disadvantage of CipR gonococci can be overcome by selection for 
compensatory mutations. Vaginal inoculation of estradiol-treated BALB/c mice with 
populations of CipS or CipI gonococci (white) mixed with similar numbers of CipR gonococci 
(black) results in the recovery of a higher proportion of CipS or CipI CFU, with some mice 
clearing the CipR bacteria. However, in 10-17% of mice tested, high numbers of only CipR 
CFU were recovered as infection progressed, most likely due to compensatory mutations 
(Kunz et al, In Press).  
The basis for the reported in vivo fitness benefit shown by gyrA mutants in N. gonorrhoeae or 
C. jejuni (Luo et al., 2005) is not known. As topoisomerase mutations are accompanied by 
alterations in supercoiling (Bagel et al., 1999; Luo et al., 2005), changes in the expression of 
genes important for colonization, growth on mucosal surfaces, or evasion of host defenses 
are one possible explanation (Luo et al., 2005; Zhang et al., 2006). It is also possible that the 
in vivo fitness benefit exhibited by gyrA91/95 mutants in N. gonorrhoeae is due to secondary 
mutations that were selected to compensate for alterations in GyrA as proposed by 
Marcusson et al. to explain the increased fitness of gyrA mutants of E. coli in a urinary tract 
infection model (Marcusson et al., 2009). The E. coli mutants tested in this study showed 
various degrees of fitness costs in vitro, however, and thus it is reasonable to assume that 
one or more compensatory mutations would be needed to promote fitness in vivo. In 
contrast, while gyrA mutations are associated with increased in vivo fitness in C. jejuni (Luo 
et al., 2005) and N. gonorrhoeae (Kunz et al., In Press), these mutations do not confer a 
significant growth cost in vitro; therefore, secondary mutations that restore growth may not 
be required for full fitness in vivo. Additionally, while not definitive evidence that gyrA 
mutations alone are responsible for the fitness we observe in the mouse model, we recently 
demonstrated that gyrA91/95 mutations are accompanied by a pronounced fitness benefit in 
two other N. gonorrhoeae strains, and that this benefit was detected within one day of 
infection (Jonathan A. D’Ambrozio & Ann E. Jerse, unpublished observation).  
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Identification of the mechanism by which gyrA mutations enhance gonococcal fitness during 
experimental murine infection is important as it may reveal new and interesting facets of 
gonococcal pathogenesis. Additionally, our data suggest CipI strains may serve as a 
reservoir for CipR in N. gonorrhoeae since a single step mutation in parC is all that is then 
required for high-level resistance. We postulate the following scenario by which this may 
occur. First, low-levels of antibiotic pressure due to fluoroquinolone treatment for other 
infections or self-medication selects for CipI strains. CipI strains are then maintained within 
sexual networks, or even flourish, due to the fitness benefit conferred by the gyrA91/95 
mutations. Highly CipR strains would not flourish, possibly due to the more severe growth 
defect construed by mutation in parC86 or the possibility that the parC86 mutation or the 
combination of the parC86, gyrA91/95 mutations may have a negative impact on the expression 
of genes important for survival in vivo. However, some CipR gonococci will be selected due 
to compensatory mutations that restore fitness while maintaining high level CipR. 
Continued study of the frequency and nature of compensatory mutations that allow 
maintenance of high level CipR is important for understanding the spread of QRNG. 
4. Conclusion 
Antibiotic resistance expressed by many of the bacterial pathogens that infect humans 
represents one of the most important public health challenges for clinical medicine in the 21st 
century. During the early years of the antibiotic era of medicine (circa. 1945-1950) it became 
clear to physicians that antibiotic treatment failures were frequently the result of the infecting 
bacteria being resistant to the antibiotic being used; indeed, penicillinase-producing strains of 
Staphylococcus aureus were recognized and became wide-spread soon after penicillin was 
introduced as a therapeutic agent in 1943 (Bud, 2007). As the antibiotic era progressed and 
more antibiotics became available, disturbing reports of treatment failures became more 
prevalent. Fortunately, researchers trained in microbial physiology and bacterial genetics 
undertook studies to learn the mechanisms used by bacteria to resist a given antibiotic. These 
early investigators soon learned that while an antibiotic resistant strain had an advantage over 
a susceptible strain in the presence of the antibiotic in question, the resistance mechanism 
frequently came at a cost in the absence of the antibiotic. Thus, in the absence of the selective 
pressure brought by the antibiotic, the resistant strain frequently grew slower in vitro and in 
model systems of infection (cell culture or animals). However, for some resistance 
mechanisms, there was little if any cost when compared to a sensitive, but otherwise isogenic 
strain. The resulting dogma from this work was that antibiotic resistance in the absence of 
selective pressures could be costly for bacteria. In this case, removing the selective pressure 
would result in the evolution of more susceptible strains that would have an advantage in the 
community. By and large, this has not been the case (Anderson & Hughes, 2010). 
Less clear, however, was whether in the absence of selective pressure, a resistant strain would 
have a fitness benefit during an infection over a sensitive counterpart. In this respect, the 
report of Luo et al. (2005) dealing with the increased fitness of a ciprofloxacin resistant strain of 
C. jejuni over a sensitive parent strain in vivo was a “game-changer” for antibiotic resistance 
researchers. Briefly, it forced us to consider the rather scary possibility that a mechanism of 
antibiotic resistance can actually enhance the ability of a pathogen to survive in the 
community. This possibility has a number of important implications for our understanding of 
bacterial pathogenesis and bacterial infections that should be considered. First, are there 
www.intechopen.com
Clinically Relevant Antibiotic Resistance Mechanisms 
Can Enhance the In Vivo Fitness of Neisseria gonorrhoeae 
 
381 
“antibiotic substitutes” in vivo that the resistance mechanism recognizes, allowing the resistant 
strain to out-compete the sensitive strain? Might these “host antibiotics” provide the selective 
pressure in the community? This is certainly likely for the fitness benefit imparted to those N. 
gonorrhoeae strains that over-express the Mtr efflux pump system. This pump, along with 
similar pumps produced by other Gram-negatives (Shafer et al., 2010), recognizes host 
antimicrobials (e.g., antimicrobial peptides) in addition to antibiotics such as beta-lactams and 
macrolides. In this context, efflux pump inhibitors (Lomovskaya & Bostian, 2006) may have 
clinical use as they would increase bacterial susceptibility to classical antibiotics as well as host 
antimicrobials. A second issue that requires further investigation is whether a resistance 
mechanism has secondary effects on the physiology of the resistant strain that results in an 
advantage during infection. This hypothesis may help to explain why gyrA91/95 mutations can 
enhance the fitness of CipI strains of N. gonorrhoeae. Hopefully, ongoing transcriptional 
profiling studies that compare isogenic CipI and CipS strains will provide insights that will 
help us to understand fitness differences. A third point merits consideration: stable mutations 
that decrease bacterial susceptibility to a given antibiotic, but not to an extent that it pushes 
them across the MIC breakpoint, may be more advantageous for the bacteria than previously 
thought. In this respect, as emphasized throughout this text, mutations in mtrR or gyrA 
provide gonococci with a fitness advantage in vivo, but do not push them across the MIC 
breakpoint for either beta-lactams or quinolones, respectively. Importantly, both are necessary 
for clinically significant levels of resistance imparted by other mutations. Accordingly, strains 
bearing mtrR and/or gyrA mutations may not only be more fit during infection, but also more 
likely to subsequently develop clinical resistance to beta-lactams and quinolones than fully 
sensitive strains. This issue is of greater urgency now because the gonococcal strain that 
caused a ceftriaxone-resistant infection in Japan is an mtrR mutant (Ohnishi et al., 2011) even 
though the mutation by itself has little impact on the level of beta-lactam resistance (Veal & 
Shafer, 2003). Finally, if a resistance mutation enhances fitness and is stably maintained in a 
bacterial pathogen for years, it may be yet another reason why antibiotic re-cycling after 
extended absence from the treatment regimen may not be a viable option to combat the 
emergence and spread of antibiotic resistant bacteria.  
We have used N. gonorrhoeae as a model human pathogen for studies on how bacterial fitness 
can be impacted by mechanisms of antibiotic resistance. Having been intimately associated 
with humans for thousands of years, it is of no surprise that the gonococcus has evolved novel 
ways to evade or resist the multitude of toxic agents that it encounters during infection. The 
continued emergence of strains expressing decreased susceptibility or even clinical resistance 
to frontline antibiotics used today (e.g., ceftriaxone) in therapy emphasizes the remarkable 
adaptive ability of this pathogen. The examples provided herein with the gonococcus 
emphasize that mechanisms of antibiotic resistance can enhance bacterial virulence, as defined 
by increased in vivo fitness. Understanding the processes that lead to increased fitness of the 
gonococcus (or any other pathogen) due to antibiotic resistance may result in novel strategies 
that could be used to inhibit bacterial replication in vivo directly or indirectly by enhancing the 
efficacy of the defensive systems of the host that operate locally. 
5. Acknowledgments 
This work was supported by the National Institute of Allergy and Infectious Diseases at the 
National Institute of Health [RO1 AI42053 and U19 AI31496 to A.E.J.; R37 AI21150 to 
www.intechopen.com
 
Antibiotic Resistant Bacteria – A Continuous Challenge in the New Millennium 
 
382 
W.M.S.], and a USUHS training grant [C073-RT to A.N.K.]. W.M.S. was supported in part by 
a Senior Research Career Scientist Award from the VA Medical Research Service. 
6. References 
Andersson, D. & Levin, B. (1999) The Biological Cost of Antibiotic Resistance. Current 
Opinion in Microbiology, Vol. 2, No. 5, pp. 489 – 493, ISSN 1369-5274 
Andersson, D. & Hughes, D. (2010) Antibiotic Resistance and Its Cost: Is It Possible to 
Reverse Resistance? Nature Reviews Microbiology, Vol. 8, No. 4, pp. 260 – 271, ISSN 
1740 - 1526 
Bagel, S., Hullen, V., Wiedemann, B. & Heisig, P. (1999) Impact of gyrA and parC Mutations on 
Quinolone Resistance, Doubling Time, and Supercoiling Degree in Escherichia coli. 
Antimicrobial Agents and Chemotherapy, Vol. 43, No. 4, pp. 868-875, ISSN 0066-4804 
Balsalobre, L., Ferrandiz, J., de Alba, G. & de la Campa, A. (2011) Nonoptimal DNA 
Topoisomerases Allow Maintenance of Supercoiling Levels and Improve Fitness of 
Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, Vol. 55, No. 3, pp. 
1097-1105, ISSN 0066-4804 
Bates, A., Berger, J. & Maxwell, A. (2011) The Ancestral Role of ATP Hydrolysis in Type II 
Topoisomerases: Prevention of DNA Double-Strand Breaks. Nucleic Acids Research, 
Vol. 39, No. 15, pp. 6327 – 6339, ISSN 0305-1048 
Belland, R., Morrison, S., Ison, C. & Huang, W. (1994) Neisseria gonorrhoeae Acquires 
Mutations in Analogous Regions of gyrA and parC in Fluoroquinolone-Resistant 
Isolates. Molecular Microbiology, Vol. 14, No. 2, pp. 371-380, ISSN 0950-382X 
Bjorkman J., Hughes, D. & Andersson, D. (1998) Virulence of Antibiotic-Resistant Salmonella 
typhimurium. Proceedings of the National Acadamy of Science, USA, Vol. 95, No. 7, pp. 
3949-3953, ISSN 0027-8424 
Bjorkholm, B., Sjolund, M., Falk, P., Berg, O., Engstrand, L. & Andersson, D. (2001) Mutation 
Frequency and Biological Cost of Antibiotic Resistance in Helicobacter pylori. 
Proceedings of the National Acadamy of Science, USA, Vol. 98, No. 25, pp. 146077-
14612, ISSN 0027-8424 
Bud, R. (2007) Fighting Resistance with Technology. In: Penicillin: Triumph and Tragedy, pp. 
116 – 139, Oxford University Press, ISBN 978-0-19-925406-4, Oxford, UK 
Centers for Disease Control and Prevention (CDC). (2007) Update to CDC's Sexually 
Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer 
Recommended for Treatment of Gonococcal Infections. Morbidity and Mortality 
Weekly Report, Vol. 56, pp. 332-336 
Chen, F.-J. & Lo, H.-J. (2003) Molecular Mechanisms of Fluoroquinolone Resistance. Journal 
of Microbiology, Immunology, and Infection, Vol. 36, No. 1, pp. 1-9, ISSN 1684-1182 
Covino, J., Cummings, M., Smith, B., Benes, S., Draft, K. & McCormack, W. (1990) Comparison 
of Ofloxacin and Ceftriaxone in the Treatment of Uncomplicated Gonorrhea Caused 
by Penicillinase-Producing and Non-Penicillinase-Producing Strains. Antimicrobial 
Agents and Chemotherapy, Vol. 34, No. 1, pp. 148–149, ISSN 0066-4804 
Delahay, R., Robertson, B., Balthazar, J., Shafer, W. & Ison, C. (1997) Involvement of the 
Gonococcal MtrE Protein in the Resistance of Neisseria gonorrhoeae to Toxic 
Hydrophobic Agents. Microbiology, Vol. 143, No. 7, pp. 2127 – 2133, ISSN 0002-1485 
Dewi, B., Akira, S., Hayashi, H. & Ba-Thein, W. (2004) High Occurrence of Simultaneous 
Mutations in Target Enzymes and MtrRCDE Efflux System in Quinolone-Resistant 
www.intechopen.com
Clinically Relevant Antibiotic Resistance Mechanisms 
Can Enhance the In Vivo Fitness of Neisseria gonorrhoeae 
 
383 
Neisseria gonorrhoeae. Sexually Transmitted Diseases, Vol. 31, No. 6, pp. 353-359, ISSN 
0148-5717 
Dionne-Odom, J., Tambe, P., Yee, E., Weinstock, H. & del Rio, C. (2011) Antimicrobial 
Resistant Gonorrhea in Atlanta: 1988 – 2006. Sexually Transmitted Diseases, Vol. 38, 
No. 12, pp. 780 – 782, ISNN 0148-5717 
Eisenstein, B. & Sparling, P. (1978) Mutations to Increased Antibiotic Susceptibility in 
Naturally-Occurring Gonococci. Nature, Vol. 271, No. 5642, pp. 242 – 244, ISSN 
0028-0836 
Emmerson, A. M. (2003) The Quinolones: Decades of Development and Use. U.S. Patent 
90001. Journal of Antimicrobial Chemotherapy, Vol. 51, Suppl1, pp. 13–20 
Folster, J. & Shafer, W. (2005) Regulation of mtrF Expression in Neisseria gonorrhoeae and Its 
Role in High-Level Antimicrobial Resistance. Journal of Bacteriology, Vol. 187, N. 11, 
pp. 3713 – 3720, ISSN 0021-9193 
Ghanem, K., Giles, J. & Zenilman, J. (2005) Fluoroquinolone-Resistant Neisseria gonorrhoeae: 
the Inevitable Epidemic. Infectious Disease Clinics of North America, Vol. 19, No. 2, 
pp. 351–365, ISSN 0891-5520 
Giraud, E., Brisabois, A., Martel, J.-L. & Chaslus-Danclai, E. (1999) Comparative Studies of 
Mutations in Animal Isolates and Experimental in vitro- and in vivo-Selected 
Mutants of Salmonella spp. Suggest a Counterselection of Highly Fluoroquinolone-
Resistant Strains in the Field. Antimicrobial Agents and Chemotherapy, Vol. 43, No. 9, 
pp. 2131-2137, ISSN 0066-4804 
Hagman, K. & Shafer, W. (1995) Transcriptional Control of the mtr Efflux System of Neisseria 
gonorrhoeae. Journal of Bacteriology, Vol. 177, No. 14, pp. 4162 – 4165, ISSN 0021-9193 
Hagman, K., Pan, W., Spratt, B., Balthazar, J., Judd, R. & Shafer, W. (1995) Resistance of 
Neisseria gonorrhoeae to Antimicrobial Hydrophobic Agents is Modulated by the 
mtrRCDE Efflux System. Microbiology, Vol. 141, No. 3, pp. 611 – 622, ISSN 0001-9400 
Hagman, K., Lucas, C., Balthazar, J., Snyder, L., Nilles, M., Judd, R. & Shafer, W. (1997) The MtrD 
Protein of Neisseria gonorrhoeae is a Member of the Resistance/Nodulation/Division 
Protein Family Constituting Part of an Efflux System. Microbiology, Vol. 143, No. 7, 
pp. 2117 – 2125, ISSN 0002-1486 
Hoffmann, K., Williams, D., Shafer, W. & Brennan, R. (2005) Characterization of the Multiple 
Transferable Resistance Repressor, MtrR from Neisseria gonorrhoeae. Journal of 
Bacteriology, Vol. 187, No 14, pp. 5008 – 5012, ISSN 0021-9193 
Hooper, D. (1999) Mode of Action of Fluoroquinolones. Drugs, Vol. 58, Suppl 2, pp. 6–10, 
ISSN 0012-6667 
Jerse, A. (1999) Experimental Gonococcal Genital Tract Infection and Opacity Protein 
Expression in Estradiol-Treated Mice. Infection and Immunity Vol. 67, No 11, pp. 
5699-5708, ISSN 0019-9567 
Jerse, A., Sharma, N., Simms, A., Crow, E., Snyder, L. & Shafer, W. (2003) A Gonococcal Efflux 
Pump System Enhances Bacterial Survival in a Female Mouse Model of Genital Tract 
Infection. Infection and Immunity, Vol. 71, No. 10, pp. 4476 – 5582, ISSN 0019-9567 
Kam, K., Kam, S., Cheung, D., Tung, V., Au, W. & Cheung, M. (2003) Molecular 
Characterization of Quinolone-Resistant Neisseria gonorrhoeae in Hong Kong. 
Antimicrobial Agents and Chemotherapy, Vol 47, No. 1, pp. 436–439, ISSN 0066-4804 
Komp Lindgren P., Marcusson, L., Sandvang, D., Frimodt-Moller, N. & Hughes, D. (2005) 
Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in 
www.intechopen.com
 
Antibiotic Resistant Bacteria – A Continuous Challenge in the New Millennium 
 
384 
Escherichia coli Implicated in Urinary Tract Infections. Antimicrobial Agents and 
Chemotherapy, Vol. 49, No. 6, pp. 2343-2351, ISSN 0066-4804 
Kunz A., Begum, A., Wu, H., D'Ambrozio, J., Robinson, J., Shafer, W., Bash, M. & Jerse, A. 
(2012), Impact of Fluoroquinolone Resistance Mutations on Gonococcal Fitness and 
in vivo Selection for Compensatory Mutations. Journal of Infectious Diseases (In Press) 
Laponogov, I., Sohi, M., Veselkov, D., Pan, X.-S., Sawhney, R., Thompson, A., McAuley, K., 
Fisher, L. & Sanderson, M. (2009) Structural Insight into the Quinolone–DNA 
Cleavage Complex of Type IIA Topoisomerases. Nature Structural and Molecular 
Biology, Vol. 16, No. 6, pp. 667–669, ISSN 1545-9993 
Lomovskaya, O. & Bostian, K. (2006) Practical Applications and Feasibility of Efflux Pump 
Inhibitors in the Clinic—A Vision for Applied Use. Biochemical Pharmacology, Vol. 
71, No. 7, pp. 910 – 918, ISSN 0006-2952 
Lucas, C., Balthazar, J., Hagman, K. & Shafer, W. (1997) The MtrR Repressor Binds the DNA 
Sequence between the mtrR and mtrC Genes of Neisseria gonorrhoeae. Journal of 
Bacteriology, Vol. 179, No. 13, pp. 4123 – 4128, ISSN 0021-9193 
Luo, N., Pereira, S., Sahin, O., Lin, J., Huang, S., Michel, L. & Zhang, Q. (2005) Enhanced in 
vivo Fitness of Fluoroquinolone-Resistant Campylobacter jejuni in the Absence of 
Antibiotic Selection Pressure. Proceedings of the National Acadamy of Science, USA, 
Vol. 102, No. 3, pp. 541-546, ISSN 0027-8424 
Marcusson L., Frimodt-Moller, N. & Hughes, D. (2009) Interplay in the Selection of 
Fluoroquinolone Resistance and Bacterial Fitness. PLoS Pathogens, Vol. 5, No. 8, pp. 
e1000541, ISSN 1553-7366 
Morais Cabral, J., Jackson, A., Smith, C., Shikotra, N., Maxwell, A. & Liddington, R. (1997) 
Crystal Structure of the Breakage-Reunion Domain of DNA Gyrase. Nature, Vol. 
388, No. 6645, pp. 903–906, ISSN 0028-0836 
Morris S., Moore, D., Hannah, P., Wang, S., Wolfe, J., Trees, D., Bolan, G. & Bauer, H. (2009) 
Strain Typing and Antimicrobial Resistance of Fluoroquinolone-Resistant Neisseria 
gonorrhoeae Causing a California Infection Outbreak. Journal of Clinical Microbiology, 
Vol. 47, No. 9, pp. 2944-2949, ISSN 0095-1137 
Morse, S., Lysko, P., McFarland, L., Knapp, J., Sandstrom, E., Critchlow, C. & Holmes, K. 
(1982) Gonococcal Strains from Homosexual Men have Outer Membranes with 
Reduced Permeability to Hydrophobic Molecules. Infection and Immunity, Vol. 37, 
No. 2, pp. 432 – 438, ISSN 0019-9567 
Mercante, A.D., Jackson, L., Johnson, P. J. T., Stringer, V. A., Dyer, D. W., & Shafer, W. M.  
(2012) MpeR Regulates the mtr Efflux Locus in Neisseria gonorrhoeae and Modulates 
Antimicrobial Resistance by an Iron-Responsive Mechanism. Antimicrobial Agents 
and Chemotherapy, Vol. 56, No. 3, pp. 1491 - 1501, ISSN 0066-4804. 
Nagaev, I, Bjorkman, J., Andersson, D., & Hughes, D. (2001) Biological Cost and 
Compensatory Evolution in Fusidic Acid Resistant Staphylococcus aureus. Molecular 
Microbiology, Vol. 40, No. 2, pp. 443-449, ISSN 0950-382X 
Ohnishi, M., Golparian, D., Shimuta, K., Saika, T., Hoshina, S., Iwasaku, K., Nakayama, S., 
Kitawaki, J. & Unemo, M. (2011) Is Neisseria gonorrhoeae Initiating a Future Era of 
Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-
Level Resistance to Ceftriaxone. Antimicrobial Agents and Chemotherapy, Vol. 55, No. 
7, pp. 3538 – 3545, ISSN 0066-4804 
www.intechopen.com
Clinically Relevant Antibiotic Resistance Mechanisms 
Can Enhance the In Vivo Fitness of Neisseria gonorrhoeae 
 
385 
Packiam, M., Veit, S., Anderson, D., Ingalls, R. & Jerse, A. (2010) Mouse Strain-Dependent 
Differences in Susceptibility to Neisseria gonorrhoeae Infection and Induction of 
Innate Immune Responses. Infection and Immunity, Vol. 78, No. 1, pp. 433-440, ISSN 
0019-9567 
Pan, W. & Spratt, B. (1994) Regulation of the Permeability of the Gonococcal Cell Envelope 
by the mtr System. Molecular Microbiology, Vol. 11, No. 4, pp. 769 – 775, ISSN 0950-
382X 
Pope, C., Gillespie, S., Pratten, J. & McHugh, T. (2008) Fluoroquinolone-Resistant Mutants of 
Burkholderia cepacia. Antimicrobial Agents and Chemotherapy, Vol. 52, No. 3, pp. 1201-
1203, ISSN 0066-4804 
Rouquette, C., Harmon, J. & Shafer, W. (1999) Induction of the mtrCDE-Encoded Efflux 
Pump system of Neisseria gonorrhoeae Requires MtrA, an AraC-Like Protein. 
Molecular Microbiology, Vol. 33, No. 3, pp. 651 – 658, ISSN 1365-2958 
Ruiz J., Jurado, A., Garcia-Méndez, E., Marco, F., Aguilar, L., Jiménez de Anta, M. & Vila, J. 
(2001) Frequency of Selection of Fluoroquinolone-Resistant Mutants of Neisseria 
gonorrhoeae Exposed to Gemifloxacin and Four Other Quinolones. Journal of 
Antimicrobial Chemotherapy, Vol. 48, No. 4, pp. 545-548, ISSN 0305-7453 
Schrag, S., Perrot, V. & Levin, B. (1997) Adaptation to the Fitness Costs of Antibiotic 
Resistance in Escherichia coli. Proceedings of the Royal Society of Biological 
Sciences, Vol. 264, No. 1386, pp. 1287 – 1291, ISSN 0962-8452 
Shafer, W., Balthazar, J., Hagman, K. & Morse, S. (1995) Missense Mutations that Alter the 
DNA-Binding Domain of the MtrR Protein Occur Frequently in Rectal Isolates of 
Neisseria gonorrhoeae that are Resistant to Fecal Lipids. Microbiology, Vol. 141, No. 4, 
pp. 907 – 911, ISSN 0001-9525 
Shafer, W., Qu, X., Waring, A. & Lehrer, R. (1998) Modulation of Neisseria gonorrhoeae 
Susceptibility to Vertebrate Antibacterial Peptides due to a Member of the 
Resistance/Nodulation/Division Efflux Pump Family. Proceedings of the National 
Academy of Science, Vol. 95, No. 4, pp. 1829 – 1833, ISSN 0027-8424 
Shafer, W., Folster, J. & Nicholas, R. (2010) Molecular Mechanisms of Antibiotic Resistance 
Expressed by the Pathogenic Neisseria. In: Neisseria: Molecular Mechanisms of 
Pathogenesis, Genco, C. & Wetzler, L. (Ed.), pp. 245 – 267, Caister Academic Press, 
ISBN 978-1-904455-51-6, Norfolk, UK 
Song, W., Condron, S., Mocca, B., Veit, S., Hill, D., Abbas, A. & Jerse, A. (2008) Local and 
Humoral Immune Responses Against Primary and Repeat Neisseria gonorrhoeae 
Genital Tract Infections of 17ß-Estradiol-Treated Mice. Vaccine, Vol. 26, pp. 5741-
5751, ISSN 0264-410X 
Starnino, S., Conte, I., Matteelli, A., Galluppi, E., Cusini, M., Carlo, A., Delmonte, S. & 
Stefanelli, P. (2010) Trend of Ciprofloxacin Resistance in Neisseria gonorrhoeae 
Strains Isolated in Italy and Analysis of the Molecular Determinants. Diagnostic 
Microbiology and Infectious Disease, Vol. 67, No. 4, pp. 350–354, ISSN 0732-8893 
Tanaka, M., Nakayama, H., Haraoka, M., Saika, T., Kobayashi, I., & Naito, S. (2000) 
Antimicrobial Resistance of Neisseria gonorrhoeae and High Prevalence of 
Ciprofloxacin-Resistant Isolates in Japan, 1993-1998. Journal of Clinical Microbiology, 
Vol. 38, No. 2, pp. 521-525, ISSN 0095-1137 
Tapsall, J. W. (2005) Antibiotic Resistance in Neisseria gonorrhoeae. Clinical Infectious Diseases, 
Vol. 41, Suppl 4, pp. S263-8 
www.intechopen.com
 
Antibiotic Resistant Bacteria – A Continuous Challenge in the New Millennium 
 
386 
Trees, D., Sandul, A., Neal, S., Higa, H., & Knapp, J. (2001) Molecular Epidemiology of 
Neisseria gonorrhoeae Exhibiting Decreased Susceptibility and Resistance to 
Ciprofloxacin in Hawaii, 1991-1999. Sexually Transmitted Diseases, Vol. 28, No. 6, pp. 
309-14, ISSN 0148-5717 
Unemo, M., Golparian, D., Syversen, G., Vestrheim, D. & Moi, H. (2010) Two Cases of 
Verified Clinical Failures Using Internationally Recommended First-Line Cefixime 
for Gonorrhoea Treatment, Norway, 2010. Euro Surveillance, Vol. 15, No. 47, ISSN 
1025-496X 
Veal, W. & Shafer, W. (2003) Identification of a Cell Envelope Protein (MtrF) Involved in 
Hydrophobic Antimicrobial Resistance in Neisseria gonorrhoeae. Journal of 
Antimicrobial Chemotherapy, Vol. 51, No. 1, pp. 27 – 37, ISSN 0305-7453 
Vereshchagin V., Ilina, E., Malakhova, M., Zubkov, M., Sidorenko, S., Kuhanova, A. & 
Govorun, V. (2004) Fluoroquinolone-Resistant Neisseria gonorrhoeae Isolates from 
Russia: Molecular Mechanisms Implicated. Journal of Antimicrobial Chemotherapy, 
Vol. 53, No. 4, pp. 653-656, ISSN 0305-7453 
Vernel-Pauillac F., Hogan, T., Tapsall, J. & Goarant, C. (2009) Quinolone Resistance in 
Neisseria gonorrhoeae: Rapid Genotyping of Quinolone Resistance-Determining 
Regions in gyrA and parC Gene by Melting Curve Analysis Predicts Susceptibility. 
Antimicrobial Agents and Chemotherapy, Vol. 53, No. 3, pp. 1264-1267, ISSN 0066-4804 
Warner, D., Folster, J., Shafer, W. & Jerse, A. (2007) Regulation of the MtrC-MtrD-MtrE 
Efflux-Pump System Modulations the in vivo Fitness of Neisseria gonorrhoeae. Journal 
of Infectious Diseases, Vol. 196, No. 12, pp. 1804 – 1812, ISSN 0022-1899 
Warner, D., Shafer, W. & Jerse, A. (2008) Clinically Relevant Mutations that Cause 
Derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux Pump System 
Confer Different Levels of Antimicrobial Resistance and in vivo Fitness. Molecular 
Microbiology, Vol. 70, No. 2, pp. 462 – 478, ISSN 1365-2958 
Webber, M., Baily, A., Blair, J., Morgan, E., Stevents, M., Hinton, J., Ivens, A., Wain, J. & 
Piddock, L. (2009) The Global Consequence of Disruption of the AcrAB-TolC Efflux 
Pump in Salmonella enterica Includes Reduced Expression of SPI-1 and Other 
Attributes Required to Infect the Host. Journal of Bacteriology, Vol. 191, No. 13, pp. 
4276 – 4285, ISSN 0021-9193 
Xia, M., Whittington, W., Shafer, W. & Holmes, K. (2000) Gonorrhea Among Men Who Have 
Sex with Men: Outbreak Caused by a Single Genotype of Erythromycin-Resistant 
Neisseria gonorrhoeae with a Single Base Pair Deletion in the mtrR Promoter Region. 
Journal of Infectious Diseases, Vol. 181, No. 6, pp. 2080 – 2082, ISSN 0022-1899 
Xiong, X., Bromley, E., Oelschlaeger, P., Woolfson, D. & Spencer, J. (2011) Structural Insights 
into Quinolone AntibioticRresistance Mediated by Pentapeptide Repeat Proteins: 
Conserved Surface Loops Direct the Activity of a Qnr Protein from a Gram-
Negative Bacterium. Nucleic Acids Research, Vol. 39, No. 9, pp. 3917–3927, ISSN 
0305-1048 
Zhang, Q., Sahin, O., McDermott, P. & Payot, S. (2006) Fitness of Antimicrobial-Resistant 
Campylobacter and Salmonella. Microbes and Infection, Vol. 8, No. 7, pp. 1972-1978, 
ISSN 1286-4579 
Zarantonelli, L., Borthagaray, G., Lee, E. & Shafer, W. (1999) Decreased Azithromycin 
Susceptibility of Neisseria gonorrhoeae Due to mtrR Mutations. Antimicrobial Agents 
and Chemotherapy, Vol. 43, No. 10, pp. 2468 – 2472, ISSN 0066-4804 
www.intechopen.com
Antibiotic Resistant Bacteria - A Continuous Challenge in the New
Millennium
Edited by Dr. Marina Pana
ISBN 978-953-51-0472-8
Hard cover, 576 pages
Publisher InTech
Published online 04, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Antibiotic-resistant bacterial strains remain a major global threat, despite the prevention, diagnosis and
antibiotherapy, which have improved considerably. In this thematic issue, the scientists present their results of
accomplished studies, in order to provide an updated overview of scientific information and also, to exchange
views on new strategies for interventions in antibiotic-resistant bacterial strains cases and outbreaks. As a
consequence, the recently developed techniques in this field will contribute to a considerable progress in
medical research.
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